secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0000950170-23-020508
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q1 net loss $34.1M; ziftomenib enrollment outperforming projections
--------------------------------------------------------------------------------

- Net loss $34.1M vs $32.5M YoY; R&D expense $25.2M; cash $405.9M provides runway into Q4 2025.
- Phase 2 registration trial of ziftomenib in NPM1-mutant AML enrollment exceeding initial projections; 85-patient target.
- Updated Phase 1 ziftomenib data to be presented at EHA June 2023; 6/20 NPM1-mutant patients achieved CR at RP2D.
- FDA cleared IND for KO-2806, a next-generation FTI; FIT-001 Phase 1 trial expected to dose first patients H2 2023.
- First combination study KOMET-007 (ziftomenib + standards of care) to dose first patients in Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/0000950170-23-020508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017023020508/kura-20230510.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer